$RLYB Rallybio ripping premarket! 🚀 Up 56% 🔹 Big move as traders circle the pending all-stock merger with Candid Therapeutics 📈 🔹 Deal could reshape Rallybi

$RLYB Rallybio ripping premarket! 🚀 Up 56% 🔹 Big move as traders circle the pending all-stock merger with Candid Therapeutics 📈 🔹 Deal could reshape Rallybio into a stronger autoimmune-focused biotech platform 🧬 🔹 Candid’s lead asset, cizutamig, is being studied across multiple autoimmune indi…